2nd Jul 2020 07:30
Renalytix AI PLC - Cardiff, Wales-based clinical diagnostics company - Says results of a clinical KidneyIntelX validation study have undergone peer-review and have been accepted for publication in the American Society of Nephrology Journal, Kidney360. KidneyIntelX identifies patients at the highest risk of progressive kidney function decline in two distinct cohorts and clinical settings with more accuracy than existing methods. The study provides details of the primary analysis and numerous sub-analyses which demonstrate robust performance of the KidneyIntelX test in the two clinical contexts.
Current stock price: 530.00 pence
Year-to-date change: up 46%
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc